MEDIPOST obtained a patent for its high-efficient technology for culturing stem cells.

The tile of this patent is ‘Method for culturing mesenchymal stem cells according to cell size’ and the patent covers an innovative technology that can enhance the therapeutic efficacy and production efficiency of stem cell treatment drugs.

MEDIPOST has named this next-generation stem cell cultured using the patented technology as ‘SMUP-Cell‘ and is currently running a test production.

MEDIPOST expects that using this technology will significantly increase the stem cell production rate, promote development of drugs for treating intractable and rare diseases which have been difficult to combat with the existing stem cells and also significantly lower the cost of medications.

Naming this next-generation stem cell as ‘SMUP-Cell‘, MEDIPOST has been running a test production in a GMP facility and the treatment efficacy of this next-generation stem cell on specific diseases was theoretically verified for the first time acquiring this patent.